Drugs.com - Clinical Trials

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous...

Feb 9, 2025 - 21:44
 0
Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous...
Read More

Tags:

Previous Article

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Cl...

Next Article

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Pop...

Related Posts

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025  0

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

Apr 10, 2025  0

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Positive Results for Batoclimab My...

Mar 19, 2025  0